FR 149175
Latest Information Update: 22 May 2001
Price :
$50 *
At a glance
- Originator Fujisawa
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 22 May 2001 No-Development-Reported for Type-2 diabetes mellitus in Japan (Unknown route)
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 19 Aug 1997 New profile